Clinical Trials Logo

Clinical Trial Summary

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.


Clinical Trial Description

n/a


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01153828
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date November 2008
Completion date August 2012

See also
  Status Clinical Trial Phase
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Recruiting NCT05345093 - Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, Impetigo and Folliculitis N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Terminated NCT00986856 - Fucidin® Cream in the Treatment of Impetigo Phase 4
Completed NCT01397461 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Recruiting NCT02090764 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo Phase 3
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Not yet recruiting NCT01611909 - Citriodiol® and Impetigo Phase 2/Phase 3
Completed NCT03177993 - Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji N/A
Completed NCT03429595 - Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo Phase 2
Completed NCT04287777 - Safety and Efficacy of Mupirocin Gel in Children With Impetigo Phase 3
Completed NCT00626795 - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Phase 2
Completed NCT00758862 - The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Phase 2
Recruiting NCT01943136 - The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Phase 1
Completed NCT01670032 - Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Phase 2/Phase 3
Completed NCT01171326 - Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Phase 2
Completed NCT01367314 - Safety and Efficacy of Topical NVC-422 Gel in Impetigo Phase 2
Completed NCT01126268 - Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Phase 4
Completed NCT00852540 - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA Phase 3